Contact
searchSearch
HMP Global

Medical Therapies Topic Center

Featured Content

Research Highlights
Real-World Effectiveness and Safety of Risankizumab in Crohn’s Disease
08/21/2025
Rebecca Mashaw
Risankizumab demonstrates sustained clinical benefit and favorable safety in Crohn’s disease, including among ustekinumab-experienced patients.
Risankizumab demonstrates sustained clinical benefit and favorable safety in Crohn’s disease, including among ustekinumab-experienced patients.
Risankizumab demonstrates...
08/21/2025
Advances in Inflammatory Bowel Disease Network
FDA Alert
FDA Approves Both SC and IV Guselkumab for Crohn's Disease Among Adult Patients
03/24/2025
Rebecca Mashaw
This clearance follows last year's approval for ulcerative colitis and the first approval for subcutaneous and intravenous formulations to induce remission in adult patients with moderately to severely active Crohn's disease.
This clearance follows last year's approval for ulcerative colitis and the first approval for subcutaneous and intravenous formulations to induce remission in adult patients with moderately to severely active Crohn's disease.
This clearance follows last...
03/24/2025
Advances in Inflammatory Bowel Disease Network
News
Study Highlights Antibody Development and Dosing Concerns in Older IBD Patients on Infliximab
01/20/2025
Jessica Garlewicz
Dosing decisions for infliximab should prioritize disease activity and patient-specific factors rather than chronological age alone.
Dosing decisions for infliximab should prioritize disease activity and patient-specific factors rather than chronological age alone.
Dosing decisions for infliximab...
01/20/2025
Advances in Inflammatory Bowel Disease Network
News
Standard Dosing of Infliximab Effective for Steroid-Refractory ASUC
10/18/2024
Jessica Garlewicz
While infliximab proved safe and effective for inducing remission in acute severe ulcerative colitis, higher doses and varied induction strategies showed no significant change in response.
While infliximab proved safe and effective for inducing remission in acute severe ulcerative colitis, higher doses and varied induction strategies showed no significant change in response.
While infliximab proved safe and...
10/18/2024
Advances in Inflammatory Bowel Disease Network
FDA alert
FDA Alert
FDA Approves Guselkumab for Moderate to Severe Ulcerative Colitis
09/12/2024
Rebecca Mashaw
Johnson & Johnson’s guselkumab is the first and only fully-human, dual-acting monoclonal antibody that blocks IL-23 and binds to CD64.
Johnson & Johnson’s guselkumab is the first and only fully-human, dual-acting monoclonal antibody that blocks IL-23 and binds to CD64.
Johnson & Johnson’s guselkumab...
09/12/2024
Advances in Inflammatory Bowel Disease Network
Christina Ha
Video
Christina Ha, MD, on the Role of Anti-interleukins in IBD
09/10/2024
Christina Ha, MD
Dr Ha reviews her presentation from the AIBD regional on the safety and efficacy of interleukin 12/23 and interleukin 23 in the management of Crohn's disease and ulcerative colitis.
Dr Ha reviews her presentation from the AIBD regional on the safety and efficacy of interleukin 12/23 and interleukin 23 in the management of Crohn's disease and ulcerative colitis.
Dr Ha reviews her presentation...
09/10/2024
Advances in Inflammatory Bowel Disease Network
IBD Drive time logo
Podcast
IBD Drive Time: Erin Forster, MD, on Risankizumab for Ulcerative Colitis
09/03/2024
Erin Forster, MD, MPH; Millie D. Long, MD, MPH; Raymond Cross, MD
Dr Erin Forster of the Medical University of South Carolina joins IBD Drive Time hosts Dr Millie Long and Dr Raymond Cross to review results of the trials for risankizumab in ulcerative colitis and discuss its positioning in treatment.
Dr Erin Forster of the Medical University of South Carolina joins IBD Drive Time hosts Dr Millie Long and Dr Raymond Cross to review results of the trials for risankizumab in ulcerative colitis and discuss its positioning in treatment.
Dr Erin Forster of the Medical...
09/03/2024
Advances in Inflammatory Bowel Disease Network
News
Subcutaneous Ustekinumab Cost Rose 84% Under Medicare Part D, Set to Drop Under Negotiated Price Reduction
08/15/2024
Rebecca Mashaw
Coverage changes omitted self-injected therapies from Part B, HHS Inspector General Reports
Coverage changes omitted self-injected therapies from Part B, HHS Inspector General Reports
Coverage changes omitted...
08/15/2024
Advances in Inflammatory Bowel Disease Network
FDA alert
FDA Alert
FDA Requires Warning Label Change for Thiopurines
08/13/2024
Rebecca Mashaw
The agency stated that rare cases of intrahepatic cholestasis of pregnancy have been reported among pregnant patients treated with thiopurines for inflammatory bowel disease and systemtic lupus erythematosus.
The agency stated that rare cases of intrahepatic cholestasis of pregnancy have been reported among pregnant patients treated with thiopurines for inflammatory bowel disease and systemtic lupus erythematosus.
The agency stated that rare...
08/13/2024
Advances in Inflammatory Bowel Disease Network
News
Upadacitinib vs Tofacitinib for Clinical Remission in Ulcerative Colitis
08/09/2024
Jolynn Tumolo
Investigators conducted a head-to-head trial of the 2 JAK inhibitors to determine which performed best in achieving steroid-free clinical remission among patients with ulcerative colitis
Investigators conducted a head-to-head trial of the 2 JAK inhibitors to determine which performed best in achieving steroid-free clinical remission among patients with ulcerative colitis
Investigators conducted a...
08/09/2024
Advances in Inflammatory Bowel Disease Network
Shubha Bhat
Podcast
Shubha Bhat, PharmD, on the Role of the Clinical Pharmacist in IBD
07/25/2024
Dr Bhat reports on the recent systematic review and RAND consensus process to define the role of the clinical pharmacist in caring for patients with inflammatory bowel disease.
Dr Bhat reports on the recent systematic review and RAND consensus process to define the role of the clinical pharmacist in caring for patients with inflammatory bowel disease.
Dr Bhat reports on the recent...
07/25/2024
Advances in Inflammatory Bowel Disease Network

News

Research Highlights
Real-World Effectiveness and Safety of Risankizumab in Crohn’s Disease
08/21/2025
Rebecca Mashaw
Risankizumab demonstrates sustained clinical benefit and favorable safety in Crohn’s disease, including among ustekinumab-experienced patients.
Risankizumab demonstrates sustained clinical benefit and favorable safety in Crohn’s disease, including among ustekinumab-experienced patients.
Risankizumab demonstrates...
08/21/2025
Advances in Inflammatory Bowel Disease Network
FDA Alert
FDA Approves Both SC and IV Guselkumab for Crohn's Disease Among Adult Patients
03/24/2025
Rebecca Mashaw
This clearance follows last year's approval for ulcerative colitis and the first approval for subcutaneous and intravenous formulations to induce remission in adult patients with moderately to severely active Crohn's disease.
This clearance follows last year's approval for ulcerative colitis and the first approval for subcutaneous and intravenous formulations to induce remission in adult patients with moderately to severely active Crohn's disease.
This clearance follows last...
03/24/2025
Advances in Inflammatory Bowel Disease Network
News
Standard Dosing of Infliximab Effective for Steroid-Refractory ASUC
10/18/2024
Jessica Garlewicz
While infliximab proved safe and effective for inducing remission in acute severe ulcerative colitis, higher doses and varied induction strategies showed no significant change in response.
While infliximab proved safe and effective for inducing remission in acute severe ulcerative colitis, higher doses and varied induction strategies showed no significant change in response.
While infliximab proved safe and...
10/18/2024
Advances in Inflammatory Bowel Disease Network
FDA alert
FDA Alert
FDA Approves Guselkumab for Moderate to Severe Ulcerative Colitis
09/12/2024
Rebecca Mashaw
Johnson & Johnson’s guselkumab is the first and only fully-human, dual-acting monoclonal antibody that blocks IL-23 and binds to CD64.
Johnson & Johnson’s guselkumab is the first and only fully-human, dual-acting monoclonal antibody that blocks IL-23 and binds to CD64.
Johnson & Johnson’s guselkumab...
09/12/2024
Advances in Inflammatory Bowel Disease Network
FDA alert
FDA Alert
FDA Requires Warning Label Change for Thiopurines
08/13/2024
Rebecca Mashaw
The agency stated that rare cases of intrahepatic cholestasis of pregnancy have been reported among pregnant patients treated with thiopurines for inflammatory bowel disease and systemtic lupus erythematosus.
The agency stated that rare cases of intrahepatic cholestasis of pregnancy have been reported among pregnant patients treated with thiopurines for inflammatory bowel disease and systemtic lupus erythematosus.
The agency stated that rare...
08/13/2024
Advances in Inflammatory Bowel Disease Network
News
Upadacitinib vs Tofacitinib for Clinical Remission in Ulcerative Colitis
08/09/2024
Jolynn Tumolo
Investigators conducted a head-to-head trial of the 2 JAK inhibitors to determine which performed best in achieving steroid-free clinical remission among patients with ulcerative colitis
Investigators conducted a head-to-head trial of the 2 JAK inhibitors to determine which performed best in achieving steroid-free clinical remission among patients with ulcerative colitis
Investigators conducted a...
08/09/2024
Advances in Inflammatory Bowel Disease Network
News
FDA Approves Interchangeable Biosimilar for Ustekinumab
11/02/2023
The biosimilar was also approved to treat moderate to severe plaque psoriasis and active psoriatic arthritis.
The biosimilar was also approved to treat moderate to severe plaque psoriasis and active psoriatic arthritis.
The biosimilar was also approved...
11/02/2023
Advances in Inflammatory Bowel Disease Network
FDA alert
FDA Alert
FDA Approves Mirikizumab for Adults With Moderately to Severely Active Ulcerative Colitis
10/27/2023
Rebecca Mashaw
The LUCENT trial demonstrated the safety and efficacy of the interleukin-23/p19 subunit inhibitor.
The LUCENT trial demonstrated the safety and efficacy of the interleukin-23/p19 subunit inhibitor.
The LUCENT trial demonstrated...
10/27/2023
Advances in Inflammatory Bowel Disease Network
News
FDA Approves New Oral Treatment for Ulcerative Colitis
10/13/2023
Priyam Vora
The U.S. Food and Drug Administration approved etrasimod for the treatment of moderate to severe ulcerative colitis among adults.
The U.S. Food and Drug Administration approved etrasimod for the treatment of moderate to severe ulcerative colitis among adults.
The U.S. Food and Drug...
10/13/2023
Advances in Inflammatory Bowel Disease Network
Research Highlights
Persistent Prothrombotic State Observed in Patients With ASUC
09/04/2025
Rebecca Mashaw
New findings show patients with acute severe ulcerative colitis remain at elevated thrombotic risk for up to 12 weeks post-hospitalization.
New findings show patients with acute severe ulcerative colitis remain at elevated thrombotic risk for up to 12 weeks post-hospitalization.
New findings show patients with...
09/04/2025
Advances in Inflammatory Bowel Disease Network
Research Highlights
Upadacitinib Improves Outcomes in Fistulizing Crohn’s Disease
09/04/2025
Rebecca Mashaw
Patients with fistulizing Crohn’s disease achieved higher rates of fistula resolution and clinical response with upadacitinib versus placebo.
Patients with fistulizing Crohn’s disease achieved higher rates of fistula resolution and clinical response with upadacitinib versus placebo.
Patients with fistulizing...
09/04/2025
Advances in Inflammatory Bowel Disease Network
Research Highlights
Pelvic MRI Detects Subclinical Perianal Disease in Pediatric Crohn’s Disease
09/04/2025
Jessica Garlewicz
The study highlights a diagnostic blind spot in pediatric CD management and supports adding baseline pelvic MRI to initial workup, even in the absence of perianal symptoms.
The study highlights a diagnostic blind spot in pediatric CD management and supports adding baseline pelvic MRI to initial workup, even in the absence of perianal symptoms.
The study highlights a...
09/04/2025
Advances in Inflammatory Bowel Disease Network
Research Highlights
Mirikizumab Improves Quality of Life and Work Productivity in Moderate to Severe Crohn’s Disease
09/04/2025
Jessica Garlewicz
Study findings highlight mirikizumab as a therapeutic option that delivers not only symptom relief but also sustained improvements in quality of life and functional outcomes for patients with moderate to severe CD.
Study findings highlight mirikizumab as a therapeutic option that delivers not only symptom relief but also sustained improvements in quality of life and functional outcomes for patients with moderate to severe CD.
Study findings highlight...
09/04/2025
Advances in Inflammatory Bowel Disease Network
Research Highlights
Risankizumab Improves Symptom Resolution and Quality of Life in Ulcerative Colitis
09/04/2025
Jessica Garlewicz
Risankizumab led to earlier and sustained improvements in individual symptoms—including abdominal pain, bowel urgency, fecal incontinence, and sleep interruption
Risankizumab led to earlier and sustained improvements in individual symptoms—including abdominal pain, bowel urgency, fecal incontinence, and sleep interruption
Risankizumab led to earlier and...
09/04/2025
Advances in Inflammatory Bowel Disease Network
Research Highlights
Guselkumab Demonstrates Efficacy and Safety in Moderate-to-Severe Crohn’s Disease
09/04/2025
Jessica Garlewicz
The study met all primary and multiplicity-controlled secondary endpoints, including clinical and endoscopic outcomes through 48 weeks.
The study met all primary and multiplicity-controlled secondary endpoints, including clinical and endoscopic outcomes through 48 weeks.
The study met all primary and...
09/04/2025
Advances in Inflammatory Bowel Disease Network
News
Validation of a Simple Ultrasound Score for Crohn’s Disease
08/28/2025
Rebecca Mashaw
A multicenter study confirms the accuracy and reliability of a simplified ultrasound score for assessing Crohn’s disease activity.
A multicenter study confirms the accuracy and reliability of a simplified ultrasound score for assessing Crohn’s disease activity.
A multicenter study confirms the...
08/28/2025
Advances in Inflammatory Bowel Disease Network
Research Highlights
Real-World Effectiveness and Safety of Risankizumab in Crohn’s Disease
08/21/2025
Rebecca Mashaw
Risankizumab demonstrates sustained clinical benefit and favorable safety in Crohn’s disease, including among ustekinumab-experienced patients.
Risankizumab demonstrates sustained clinical benefit and favorable safety in Crohn’s disease, including among ustekinumab-experienced patients.
Risankizumab demonstrates...
08/21/2025
Advances in Inflammatory Bowel Disease Network
Research Highlights
Intestinal Ultrasound Activity in Pregnancy Predicts Adverse Outcomes in Women With Inflammatory Bowel Disease
08/21/2025
Rebecca Mashaw
Intestinal ultrasound during pregnancy may more reliably predict adverse maternal and neonatal outcomes from inflammatory bowel disease than clinical or biochemical assessments alone, recent research revealed.
Intestinal ultrasound during pregnancy may more reliably predict adverse maternal and neonatal outcomes from inflammatory bowel disease than clinical or biochemical assessments alone, recent research revealed.
Intestinal ultrasound during...
08/21/2025
Advances in Inflammatory Bowel Disease Network
Research Highlights
Undiagnosed Spondyloarthritis Common Among IBD Patients
08/11/2025
Jessica Garlewicz
Integrating brief questionnaires like IBIS-Q into clinic workflows may facilitate earlier SpA recognition, improve interdisciplinary care coordination, and ultimately enhance long-term outcomes for patients with IBD.
Integrating brief questionnaires like IBIS-Q into clinic workflows may facilitate earlier SpA recognition, improve interdisciplinary care coordination, and ultimately enhance long-term outcomes for patients with IBD.
Integrating brief questionnaires...
08/11/2025
Rheumatology & Arthritis

Insights

IBD Drive time logo
Podcast
IBD Drive Time: Erin Forster, MD, on Risankizumab for Ulcerative Colitis
09/03/2024
Erin Forster, MD, MPH; Millie D. Long, MD, MPH; Raymond Cross, MD
Dr Erin Forster of the Medical University of South Carolina joins IBD Drive Time hosts Dr Millie Long and Dr Raymond Cross to review results of the trials for risankizumab in ulcerative colitis and discuss its positioning in treatment.
Dr Erin Forster of the Medical University of South Carolina joins IBD Drive Time hosts Dr Millie Long and Dr Raymond Cross to review results of the trials for risankizumab in ulcerative colitis and discuss its positioning in treatment.
Dr Erin Forster of the Medical...
09/03/2024
Advances in Inflammatory Bowel Disease Network
Shubha Bhat
Podcast
Shubha Bhat, PharmD, on the Role of the Clinical Pharmacist in IBD
07/25/2024
Dr Bhat reports on the recent systematic review and RAND consensus process to define the role of the clinical pharmacist in caring for patients with inflammatory bowel disease.
Dr Bhat reports on the recent systematic review and RAND consensus process to define the role of the clinical pharmacist in caring for patients with inflammatory bowel disease.
Dr Bhat reports on the recent...
07/25/2024
Advances in Inflammatory Bowel Disease Network
Jessica Allegretti
Video
Jessica Allegretti, MD, on Recent Advances in Anti-Interleukin Therapies
07/19/2024
Dr Allegretti provides key take-home points from her presentation at the AIBD regional meeting on how anti-interleukin therapies work to treat both Crohn's disease and ulcerative colitis,
Dr Allegretti provides key take-home points from her presentation at the AIBD regional meeting on how anti-interleukin therapies work to treat both Crohn's disease and ulcerative colitis,
Dr Allegretti provides key...
07/19/2024
Advances in Inflammatory Bowel Disease Network
Ed Loftus
Video
Edward Loftus, MD, on Upadacitinib in Crohn's Disease
06/06/2024
Dr Loftus recaps his poster presentation on a subanalysis from the upadacitinib phase 3 trials in Crohn's disease examining the effect on anxiety, depression, fatigue, and bowel urgency.
Dr Loftus recaps his poster presentation on a subanalysis from the upadacitinib phase 3 trials in Crohn's disease examining the effect on anxiety, depression, fatigue, and bowel urgency.
Dr Loftus recaps his poster...
06/06/2024
Advances in Inflammatory Bowel Disease Network
Miguel Regueiro MD
Conference Coverage
Miguel Regueiro, MD, on the SEQUENCE Study
06/03/2024
Miguel D. Regueiro, MD
Dr Regueiro recaps the results from the pivotal study comparing the effects of risankizumab with ustekinumab on key biomarkers of inflammatory bowel disease, which he presented at Digestive Disease Week 2024.
Dr Regueiro recaps the results from the pivotal study comparing the effects of risankizumab with ustekinumab on key biomarkers of inflammatory bowel disease, which he presented at Digestive Disease Week 2024.
Dr Regueiro recaps the results...
06/03/2024
Advances in Inflammatory Bowel Disease Network
Rishika Chugh
Podcast
Rishika Chugh, MD: Safety of Vedolizumab and Ustekinumab in Pregnancy
05/28/2024
Dr Chugh reviews the results of a recent study of the safety of ustekinumab and vedolizumab among pregnant patients with inflammatory bowel disease.
Dr Chugh reviews the results of a recent study of the safety of ustekinumab and vedolizumab among pregnant patients with inflammatory bowel disease.
Dr Chugh reviews the results of...
05/28/2024
Advances in Inflammatory Bowel Disease Network
Christina Ha
Video
Christina Ha, MD, on Anti-Integrins in IBD
04/27/2024
Dr Ha recaps her presentation from the AIBD regional on the use of anti-integrins, particularly vedolizumab, for treating IBD.
Dr Ha recaps her presentation from the AIBD regional on the use of anti-integrins, particularly vedolizumab, for treating IBD.
Dr Ha recaps her presentation...
04/27/2024
Advances in Inflammatory Bowel Disease Network
Ray
Video
Raymond Cross, MD, on JAK Inhibitors in IBD
04/27/2024
Dr Cross reviews his presentation from the AIBD regional meeting on the use, safety, and positioning of Janus kinase inhibitors for the treatment of IBD.
Dr Cross reviews his presentation from the AIBD regional meeting on the use, safety, and positioning of Janus kinase inhibitors for the treatment of IBD.
Dr Cross reviews his...
04/27/2024
Advances in Inflammatory Bowel Disease Network
Jordan Axelrad
Conference Coverage
Jordan Axelrad, MD, on S1P Receptor Modulators in IBD
04/06/2024
Dr Axelrad discusses his presentation at the AIBD regional meeting on the value and positioning of sphingosine 1-phosphate receptor modulators for the treatment of inflammatory bowel disease.
Dr Axelrad discusses his presentation at the AIBD regional meeting on the value and positioning of sphingosine 1-phosphate receptor modulators for the treatment of inflammatory bowel disease.
Dr Axelrad discusses his...
04/06/2024
Advances in Inflammatory Bowel Disease Network
IBD Drive time logo
Podcast
IBD Drive Time: Russell Cohen, MD, on New Therapies for IBD
12/20/2023
In this episode of IBD Drive Time, Dr Raymond Cross and Dr Russell Cohen review several new therapies and formulations that have been recently approved for treating inflammatory bowel disease and discuss how best to position these medications.
In this episode of IBD Drive Time, Dr Raymond Cross and Dr Russell Cohen review several new therapies and formulations that have been recently approved for treating inflammatory bowel disease and discuss how best to position these medications.
In this episode of IBD Drive...
12/20/2023
Advances in Inflammatory Bowel Disease Network
David Rubin
Expert Insights
David Rubin, MD, on the Top 10 Challenges in IBD
09/12/2025
David T. Rubin, MD
Dr Rubin reviews his take on the top 10 challenges in inflammatory bowel disease facing researchers and clinicians, from cost to the search for a cure.
Dr Rubin reviews his take on the top 10 challenges in inflammatory bowel disease facing researchers and clinicians, from cost to the search for a cure.
Dr Rubin reviews his take on the...
09/12/2025
Advances in Inflammatory Bowel Disease Network
PIANO Global Consensus
Gillian Watermeyer, MD, on Management of Pregnancy Among Patients With IBD
09/09/2025
Gillian Watermeyer, MD
Dr Watermeyer reviews the consensus of her panel on management of pregnancy among patients with inflammatory bowel disease.
Dr Watermeyer reviews the consensus of her panel on management of pregnancy among patients with inflammatory bowel disease.
Dr Watermeyer reviews the...
09/09/2025
Advances in Inflammatory Bowel Disease Network
PIANO Global Consensus
Mette Julsgaard, MD, on IBD Medications During Lactation
09/09/2025
Mette Julsgaard, MD
Dr Julsgaard led the group that studied and developed consensus statements on the subject of IBD medications safe to use during lactation.
Dr Julsgaard led the group that studied and developed consensus statements on the subject of IBD medications safe to use during lactation.
Dr Julsgaard led the group that...
09/09/2025
Advances in Inflammatory Bowel Disease Network
Cynthia Seow
PIANO Global Consensus
Dr Cynthia Seow on IBD Medications During Pregnancy
09/09/2025
Cynthia Seow, MD
Dr Seow discusses work of her group on the PIANO Consensus in reviewing the safety of medications for IBD during preconception, pregnancy, postpartum, breastfeeding, and over the longer term to assess affects on the children.
Dr Seow discusses work of her group on the PIANO Consensus in reviewing the safety of medications for IBD during preconception, pregnancy, postpartum, breastfeeding, and over the longer term to assess affects on the children.
Dr Seow discusses work of her...
09/09/2025
Advances in Inflammatory Bowel Disease Network
PIANO Global Consensus
Sonia Friedman, MD, on Fertility Among Patients With IBD
09/05/2025
Sonia Friedman, MD
Dr Friedman reviews the findings of her PIANO Global Consensus group on whether inflammatory bowel disease may affect fertility among patients and the effectiveness of assisted reproductive methods when needed.
Dr Friedman reviews the findings of her PIANO Global Consensus group on whether inflammatory bowel disease may affect fertility among patients and the effectiveness of assisted reproductive methods when needed.
Dr Friedman reviews the findings...
09/05/2025
Advances in Inflammatory Bowel Disease Network
PIANO Global Consensus
Emma Flanagan, MBBS, on Preconception Counseling for Patients With IBD
09/05/2025
Dr Flanagan reviews the consensus of her working group on preconception counseling and contraceptives for patients with inflammatory bowel disease.
Dr Flanagan reviews the consensus of her working group on preconception counseling and contraceptives for patients with inflammatory bowel disease.
Dr Flanagan reviews the...
09/05/2025
Advances in Inflammatory Bowel Disease Network
PIANO Global Consensus
Dr Jesus Yamamoto-Furusho on Managing IBD Activity During Pregnancy
09/05/2025
Dr Jesus Yamamoto-Furusho, who led the development of the PIANO Global Consensus statements on managing disease activity among pregnant patients with inflammatory bowel disease, gives an overview of his group's conclusions.
Dr Jesus Yamamoto-Furusho, who led the development of the PIANO Global Consensus statements on managing disease activity among pregnant patients with inflammatory bowel disease, gives an overview of his group's conclusions.
Dr Jesus Yamamoto-Furusho, who...
09/05/2025
Advances in Inflammatory Bowel Disease Network
IBD Drive time logo
Podcast
Ryan Ungaro, MD, on Perturbances in Metabolic Pathways in IBD
09/02/2025
Raymond Cross, MD; Ryan Ungaro
Dr Raymond Cross discusses with Dr Ryan Ungaro how the Mount Sinai Crohn's and Colitis Registry, a prospective observational cohort, is being studied to determine if its detailed clinical information and omics data collected can identify new...
Dr Raymond Cross discusses with Dr Ryan Ungaro how the Mount Sinai Crohn's and Colitis Registry, a prospective observational cohort, is being studied to determine if its detailed clinical information and omics data collected can identify new...
Dr Raymond Cross discusses with...
09/02/2025
Advances in Inflammatory Bowel Disease Network
Uma Mahadevan, MD
PIANO Global Consensus
Dr Uma Mahadevan on the PIANO Global Consensus on Pregnancy in IBD
08/28/2025
Uma Mahadevan, MD
Dr Uma Mahadevan, the principal investigator for the PIANO registry of IBD in pregnancy, introduces a series of reports on the Global Consensus for this groundbreaking study of the impacts of IBD and medications on fertility, conception,...
Dr Uma Mahadevan, the principal investigator for the PIANO registry of IBD in pregnancy, introduces a series of reports on the Global Consensus for this groundbreaking study of the impacts of IBD and medications on fertility, conception,...
Dr Uma Mahadevan, the principal...
08/28/2025
Advances in Inflammatory Bowel Disease Network
PIANO Global Consensus
Prof. Siew Ng on Maternal Factors Affecting Pregnancy in IBD
08/28/2025
Siew Ng, MD
Professor Siew Ng from the Chinese University of Hong Kong explains maternal factors that should be considered when managing pregnant patients with inflammatory bowel disease, based on the PIANO Global Consensus.
Professor Siew Ng from the Chinese University of Hong Kong explains maternal factors that should be considered when managing pregnant patients with inflammatory bowel disease, based on the PIANO Global Consensus.
Professor Siew Ng from the...
08/28/2025
Advances in Inflammatory Bowel Disease Network

Interactive Features

Quiz
Role of Biologic Agents in IBD
06/14/2023
Priyam Vora
Are biologic agents the ultimate answer in the treatment of intestinal inflammation? Test your knowledge here!
Are biologic agents the ultimate answer in the treatment of intestinal inflammation? Test your knowledge here!
Are biologic agents the ultimate...
06/14/2023
Advances in Inflammatory Bowel Disease Network
Quiz
Terminal Ileal Resection and CRC Risk
08/07/2025
Rebecca Mashaw
Is terminal ileum resection in patients with Crohn’s disease associated with colorectal cancer risk? See what recent research found by taking our quiz.
Is terminal ileum resection in patients with Crohn’s disease associated with colorectal cancer risk? See what recent research found by taking our quiz.
Is terminal ileum resection in...
08/07/2025
Gastroenterology
Quiz
Does Hormone Replacement Therapy Affect IBD?
07/18/2025
Can hormone replacement therapy help or harm disease activity among women with IBD? Our quiz will show the answer!
Can hormone replacement therapy help or harm disease activity among women with IBD? Our quiz will show the answer!
Can hormone replacement therapy...
07/18/2025
Advances in Inflammatory Bowel Disease Network
Quiz
Can Perspiration Reveal IBD Biomarkers?
07/18/2025
Can a wearable sensor help monitor disease activity in IBD--via sweat? Take our quiz to get the answer.
Can a wearable sensor help monitor disease activity in IBD--via sweat? Take our quiz to get the answer.
Can a wearable sensor help...
07/18/2025
Advances in Inflammatory Bowel Disease Network
Quiz
Making EHRs Work
07/01/2025
Rebecca Mashaw
Which of the following factors did clinicians say in a recent study is particularly important for EHR functionality in the context of IBD?
Which of the following factors did clinicians say in a recent study is particularly important for EHR functionality in the context of IBD?
Which of the following factors...
07/01/2025
Advances in Inflammatory Bowel Disease Network
Quiz
Do EHRs Help or Hinder in IBD Care?
07/01/2025
Rebecca Mashaw
According to a recent survey of clinicians who care for patients with inflammatory bowel disease, what percentage reported that their EHR system does not enhance patient care in IBD?
According to a recent survey of clinicians who care for patients with inflammatory bowel disease, what percentage reported that their EHR system does not enhance patient care in IBD?
According to a recent survey of...
07/01/2025
Advances in Inflammatory Bowel Disease Network
Quiz
Advanced Combination Treatment for Refractory IBD
07/01/2025
Rebecca Mashaw
A multicenter Canadian study to evaluate advanced combination treatment (ACT) in patients with refractory inflammatory bowel disease (IBD) arrived at which of the following conclusions?
A multicenter Canadian study to evaluate advanced combination treatment (ACT) in patients with refractory inflammatory bowel disease (IBD) arrived at which of the following conclusions?
A multicenter Canadian study to...
07/01/2025
Advances in Inflammatory Bowel Disease Network
Quiz
Hormone Replacement Impact on IBD
05/22/2025
Rebecca Mashaw
Does hormone replacement therapy have any effect on treatment for IBD among postmenopausal women? Take our quiz to find out!
Does hormone replacement therapy have any effect on treatment for IBD among postmenopausal women? Take our quiz to find out!
Does hormone replacement therapy...
05/22/2025
Advances in Inflammatory Bowel Disease Network
Quiz
Upper GI Crohn's Disease
03/18/2025
Rebecca Mashaw
How much do you know about upper GI Crohn's disease? Take our quiz to check your knowledge!
How much do you know about upper GI Crohn's disease? Take our quiz to check your knowledge!
How much do you know about upper...
03/18/2025
Advances in Inflammatory Bowel Disease Network
Quiz
Preoperative Nutrition for Crohn’s Disease Patients
03/18/2025
Rebecca Mashaw
What is one benefit of preoperative exclusive enteral nutrition for Crohn’s disease patients? Take our quiz to find out if you know the answer!
What is one benefit of preoperative exclusive enteral nutrition for Crohn’s disease patients? Take our quiz to find out if you know the answer!
What is one benefit of...
03/18/2025
Advances in Inflammatory Bowel Disease Network
Quiz
Risk Factors for Surgery in Crohn’s Disease
02/26/2025
Rebecca Mashaw
Estimates vary but indicate that half or more of patients with Crohn's disease will require surgery at some point in their disease course. Do you know which factors place your patients at high risk for surgery? Take our quiz to find out!
Estimates vary but indicate that half or more of patients with Crohn's disease will require surgery at some point in their disease course. Do you know which factors place your patients at high risk for surgery? Take our quiz to find out!
Estimates vary but indicate that...
02/26/2025
Advances in Inflammatory Bowel Disease Network

Latest News

Research Highlights
Real-World Effectiveness and Safety of Risankizumab in Crohn’s Disease
08/21/2025
Rebecca Mashaw
Risankizumab demonstrates sustained clinical benefit and favorable safety in Crohn’s disease, including among ustekinumab-experienced patients.
Risankizumab demonstrates sustained clinical benefit and favorable safety in Crohn’s disease, including among ustekinumab-experienced patients.
Risankizumab demonstrates...
08/21/2025
Advances in Inflammatory Bowel Disease Network
FDA Alert
FDA Approves Both SC and IV Guselkumab for Crohn's Disease Among Adult Patients
03/24/2025
Rebecca Mashaw
This clearance follows last year's approval for ulcerative colitis and the first approval for subcutaneous and intravenous formulations to induce remission in adult patients with moderately to severely active Crohn's disease.
This clearance follows last year's approval for ulcerative colitis and the first approval for subcutaneous and intravenous formulations to induce remission in adult patients with moderately to severely active Crohn's disease.
This clearance follows last...
03/24/2025
Advances in Inflammatory Bowel Disease Network
News
Standard Dosing of Infliximab Effective for Steroid-Refractory ASUC
10/18/2024
Jessica Garlewicz
While infliximab proved safe and effective for inducing remission in acute severe ulcerative colitis, higher doses and varied induction strategies showed no significant change in response.
While infliximab proved safe and effective for inducing remission in acute severe ulcerative colitis, higher doses and varied induction strategies showed no significant change in response.
While infliximab proved safe and...
10/18/2024
Advances in Inflammatory Bowel Disease Network
FDA alert
FDA Alert
FDA Approves Guselkumab for Moderate to Severe Ulcerative Colitis
09/12/2024
Rebecca Mashaw
Johnson & Johnson’s guselkumab is the first and only fully-human, dual-acting monoclonal antibody that blocks IL-23 and binds to CD64.
Johnson & Johnson’s guselkumab is the first and only fully-human, dual-acting monoclonal antibody that blocks IL-23 and binds to CD64.
Johnson & Johnson’s guselkumab...
09/12/2024
Advances in Inflammatory Bowel Disease Network
FDA alert
FDA Alert
FDA Requires Warning Label Change for Thiopurines
08/13/2024
Rebecca Mashaw
The agency stated that rare cases of intrahepatic cholestasis of pregnancy have been reported among pregnant patients treated with thiopurines for inflammatory bowel disease and systemtic lupus erythematosus.
The agency stated that rare cases of intrahepatic cholestasis of pregnancy have been reported among pregnant patients treated with thiopurines for inflammatory bowel disease and systemtic lupus erythematosus.
The agency stated that rare...
08/13/2024
Advances in Inflammatory Bowel Disease Network
News
Upadacitinib vs Tofacitinib for Clinical Remission in Ulcerative Colitis
08/09/2024
Jolynn Tumolo
Investigators conducted a head-to-head trial of the 2 JAK inhibitors to determine which performed best in achieving steroid-free clinical remission among patients with ulcerative colitis
Investigators conducted a head-to-head trial of the 2 JAK inhibitors to determine which performed best in achieving steroid-free clinical remission among patients with ulcerative colitis
Investigators conducted a...
08/09/2024
Advances in Inflammatory Bowel Disease Network
News
FDA Approves Interchangeable Biosimilar for Ustekinumab
11/02/2023
The biosimilar was also approved to treat moderate to severe plaque psoriasis and active psoriatic arthritis.
The biosimilar was also approved to treat moderate to severe plaque psoriasis and active psoriatic arthritis.
The biosimilar was also approved...
11/02/2023
Advances in Inflammatory Bowel Disease Network
FDA alert
FDA Alert
FDA Approves Mirikizumab for Adults With Moderately to Severely Active Ulcerative Colitis
10/27/2023
Rebecca Mashaw
The LUCENT trial demonstrated the safety and efficacy of the interleukin-23/p19 subunit inhibitor.
The LUCENT trial demonstrated the safety and efficacy of the interleukin-23/p19 subunit inhibitor.
The LUCENT trial demonstrated...
10/27/2023
Advances in Inflammatory Bowel Disease Network
News
FDA Approves New Oral Treatment for Ulcerative Colitis
10/13/2023
Priyam Vora
The U.S. Food and Drug Administration approved etrasimod for the treatment of moderate to severe ulcerative colitis among adults.
The U.S. Food and Drug Administration approved etrasimod for the treatment of moderate to severe ulcerative colitis among adults.
The U.S. Food and Drug...
10/13/2023
Advances in Inflammatory Bowel Disease Network
Research Highlights
Persistent Prothrombotic State Observed in Patients With ASUC
09/04/2025
Rebecca Mashaw
New findings show patients with acute severe ulcerative colitis remain at elevated thrombotic risk for up to 12 weeks post-hospitalization.
New findings show patients with acute severe ulcerative colitis remain at elevated thrombotic risk for up to 12 weeks post-hospitalization.
New findings show patients with...
09/04/2025
Advances in Inflammatory Bowel Disease Network
Research Highlights
Upadacitinib Improves Outcomes in Fistulizing Crohn’s Disease
09/04/2025
Rebecca Mashaw
Patients with fistulizing Crohn’s disease achieved higher rates of fistula resolution and clinical response with upadacitinib versus placebo.
Patients with fistulizing Crohn’s disease achieved higher rates of fistula resolution and clinical response with upadacitinib versus placebo.
Patients with fistulizing...
09/04/2025
Advances in Inflammatory Bowel Disease Network
Research Highlights
Pelvic MRI Detects Subclinical Perianal Disease in Pediatric Crohn’s Disease
09/04/2025
Jessica Garlewicz
The study highlights a diagnostic blind spot in pediatric CD management and supports adding baseline pelvic MRI to initial workup, even in the absence of perianal symptoms.
The study highlights a diagnostic blind spot in pediatric CD management and supports adding baseline pelvic MRI to initial workup, even in the absence of perianal symptoms.
The study highlights a...
09/04/2025
Advances in Inflammatory Bowel Disease Network
Research Highlights
Mirikizumab Improves Quality of Life and Work Productivity in Moderate to Severe Crohn’s Disease
09/04/2025
Jessica Garlewicz
Study findings highlight mirikizumab as a therapeutic option that delivers not only symptom relief but also sustained improvements in quality of life and functional outcomes for patients with moderate to severe CD.
Study findings highlight mirikizumab as a therapeutic option that delivers not only symptom relief but also sustained improvements in quality of life and functional outcomes for patients with moderate to severe CD.
Study findings highlight...
09/04/2025
Advances in Inflammatory Bowel Disease Network
Research Highlights
Risankizumab Improves Symptom Resolution and Quality of Life in Ulcerative Colitis
09/04/2025
Jessica Garlewicz
Risankizumab led to earlier and sustained improvements in individual symptoms—including abdominal pain, bowel urgency, fecal incontinence, and sleep interruption
Risankizumab led to earlier and sustained improvements in individual symptoms—including abdominal pain, bowel urgency, fecal incontinence, and sleep interruption
Risankizumab led to earlier and...
09/04/2025
Advances in Inflammatory Bowel Disease Network
Research Highlights
Guselkumab Demonstrates Efficacy and Safety in Moderate-to-Severe Crohn’s Disease
09/04/2025
Jessica Garlewicz
The study met all primary and multiplicity-controlled secondary endpoints, including clinical and endoscopic outcomes through 48 weeks.
The study met all primary and multiplicity-controlled secondary endpoints, including clinical and endoscopic outcomes through 48 weeks.
The study met all primary and...
09/04/2025
Advances in Inflammatory Bowel Disease Network
News
Validation of a Simple Ultrasound Score for Crohn’s Disease
08/28/2025
Rebecca Mashaw
A multicenter study confirms the accuracy and reliability of a simplified ultrasound score for assessing Crohn’s disease activity.
A multicenter study confirms the accuracy and reliability of a simplified ultrasound score for assessing Crohn’s disease activity.
A multicenter study confirms the...
08/28/2025
Advances in Inflammatory Bowel Disease Network
Research Highlights
Real-World Effectiveness and Safety of Risankizumab in Crohn’s Disease
08/21/2025
Rebecca Mashaw
Risankizumab demonstrates sustained clinical benefit and favorable safety in Crohn’s disease, including among ustekinumab-experienced patients.
Risankizumab demonstrates sustained clinical benefit and favorable safety in Crohn’s disease, including among ustekinumab-experienced patients.
Risankizumab demonstrates...
08/21/2025
Advances in Inflammatory Bowel Disease Network
Research Highlights
Intestinal Ultrasound Activity in Pregnancy Predicts Adverse Outcomes in Women With Inflammatory Bowel Disease
08/21/2025
Rebecca Mashaw
Intestinal ultrasound during pregnancy may more reliably predict adverse maternal and neonatal outcomes from inflammatory bowel disease than clinical or biochemical assessments alone, recent research revealed.
Intestinal ultrasound during pregnancy may more reliably predict adverse maternal and neonatal outcomes from inflammatory bowel disease than clinical or biochemical assessments alone, recent research revealed.
Intestinal ultrasound during...
08/21/2025
Advances in Inflammatory Bowel Disease Network
Research Highlights
Undiagnosed Spondyloarthritis Common Among IBD Patients
08/11/2025
Jessica Garlewicz
Integrating brief questionnaires like IBIS-Q into clinic workflows may facilitate earlier SpA recognition, improve interdisciplinary care coordination, and ultimately enhance long-term outcomes for patients with IBD.
Integrating brief questionnaires like IBIS-Q into clinic workflows may facilitate earlier SpA recognition, improve interdisciplinary care coordination, and ultimately enhance long-term outcomes for patients with IBD.
Integrating brief questionnaires...
08/11/2025
Rheumatology & Arthritis

Latest Podcasts

IBD Drive time logo
Podcast
IBD Drive Time: Erin Forster, MD, on Risankizumab for Ulcerative Colitis
09/03/2024
Erin Forster, MD, MPH; Millie D. Long, MD, MPH; Raymond Cross, MD
Dr Erin Forster of the Medical University of South Carolina joins IBD Drive Time hosts Dr Millie Long and Dr Raymond Cross to review results of the trials for risankizumab in ulcerative colitis and discuss its positioning in treatment.
Dr Erin Forster of the Medical University of South Carolina joins IBD Drive Time hosts Dr Millie Long and Dr Raymond Cross to review results of the trials for risankizumab in ulcerative colitis and discuss its positioning in treatment.
Dr Erin Forster of the Medical...
09/03/2024
Advances in Inflammatory Bowel Disease Network
Shubha Bhat
Podcast
Shubha Bhat, PharmD, on the Role of the Clinical Pharmacist in IBD
07/25/2024
Dr Bhat reports on the recent systematic review and RAND consensus process to define the role of the clinical pharmacist in caring for patients with inflammatory bowel disease.
Dr Bhat reports on the recent systematic review and RAND consensus process to define the role of the clinical pharmacist in caring for patients with inflammatory bowel disease.
Dr Bhat reports on the recent...
07/25/2024
Advances in Inflammatory Bowel Disease Network
Rishika Chugh
Podcast
Rishika Chugh, MD: Safety of Vedolizumab and Ustekinumab in Pregnancy
05/28/2024
Dr Chugh reviews the results of a recent study of the safety of ustekinumab and vedolizumab among pregnant patients with inflammatory bowel disease.
Dr Chugh reviews the results of a recent study of the safety of ustekinumab and vedolizumab among pregnant patients with inflammatory bowel disease.
Dr Chugh reviews the results of...
05/28/2024
Advances in Inflammatory Bowel Disease Network
IBD Drive time logo
Podcast
IBD Drive Time: Russell Cohen, MD, on New Therapies for IBD
12/20/2023
In this episode of IBD Drive Time, Dr Raymond Cross and Dr Russell Cohen review several new therapies and formulations that have been recently approved for treating inflammatory bowel disease and discuss how best to position these medications.
In this episode of IBD Drive Time, Dr Raymond Cross and Dr Russell Cohen review several new therapies and formulations that have been recently approved for treating inflammatory bowel disease and discuss how best to position these medications.
In this episode of IBD Drive...
12/20/2023
Advances in Inflammatory Bowel Disease Network
Bruce Sands
Podcast
Bruce Sands, MD, on the VEGA Study of Combination Biologic Therapy in UC
12/19/2022
Dr Sands provides an overview of the VEGA study, the first of its kind to combine 2 biologic agents to attempt to achieve higher rates of remission among patients with ulcerative colitis.
Dr Sands provides an overview of the VEGA study, the first of its kind to combine 2 biologic agents to attempt to achieve higher rates of remission among patients with ulcerative colitis.
Dr Sands provides an overview of...
12/19/2022
Advances in Inflammatory Bowel Disease Network
IBD Drive time logo
Podcast
Ryan Ungaro, MD, on Perturbances in Metabolic Pathways in IBD
09/02/2025
Raymond Cross, MD; Ryan Ungaro
Dr Raymond Cross discusses with Dr Ryan Ungaro how the Mount Sinai Crohn's and Colitis Registry, a prospective observational cohort, is being studied to determine if its detailed clinical information and omics data collected can identify new...
Dr Raymond Cross discusses with Dr Ryan Ungaro how the Mount Sinai Crohn's and Colitis Registry, a prospective observational cohort, is being studied to determine if its detailed clinical information and omics data collected can identify new...
Dr Raymond Cross discusses with...
09/02/2025
Advances in Inflammatory Bowel Disease Network
IBD Drive time logo
Podcast
Anita Afzali, MD, on the ACG Guidelines for Crohn's Disease
08/18/2025
Raymond Cross, MD; Anita Afzali
Dr Anita Afzali reviews with Dr Raymond Cross the updated guidelines for managing Crohn's disease from the American College of Gastroenterology,
Dr Anita Afzali reviews with Dr Raymond Cross the updated guidelines for managing Crohn's disease from the American College of Gastroenterology,
Dr Anita Afzali reviews with Dr...
08/18/2025
Advances in Inflammatory Bowel Disease Network
IBD Drive time logo
Podcast
IBD Drive Time: David Rubin, MD, on the ACG Guidelines for Ulcerative Colitis
08/04/2025
David T. Rubin, MD; Raymond Cross, MD
Host Raymond Cross, MD, discusses the updates in the American College of Gastroenterology guideline on managing ulcerative colitis with first author David Rubin, MD.
Host Raymond Cross, MD, discusses the updates in the American College of Gastroenterology guideline on managing ulcerative colitis with first author David Rubin, MD.
Host Raymond Cross, MD,...
08/04/2025
Advances in Inflammatory Bowel Disease Network
IBD Drive time logo
Podcast
IBD Drive Time: Corey Siegel, MD, on Defining Quality Care for IBD
07/15/2025
Raymond Cross, MD; Corey A. Siegel, MD, MS
Host Raymond Cross, MD, and Dr Corey Siegel delve into the factors that constitute quality care for patients with IBD today, and how the definition of quality care has evolved over time.
Host Raymond Cross, MD, and Dr Corey Siegel delve into the factors that constitute quality care for patients with IBD today, and how the definition of quality care has evolved over time.
Host Raymond Cross, MD, and Dr...
07/15/2025
Advances in Inflammatory Bowel Disease Network
IBD Drive time logo
Podcast
IBD Drive Time: Dr Susan Kais on Pregnancy and IBD
06/19/2025
Raymond Cross, MD
Drs Raymond Cross and Susan Kais delve into the issues surrounding fertility, pregnancy, postpartum care and more for women with IBD.
Drs Raymond Cross and Susan Kais delve into the issues surrounding fertility, pregnancy, postpartum care and more for women with IBD.
Drs Raymond Cross and Susan Kais...
06/19/2025
Advances in Inflammatory Bowel Disease Network
IBD Drive time logo
Podcast
Drs Sara Horst and Jordan Axelrad Review Studies on Infection, Malignancy With IBD Therapies
06/06/2025
Sara Horst, MD; Jordan Axelrad
Guest host Sara Horst, MD, talks with Dr Jordan Axelrad about two studies on safety of advanced therapies for inflammatory bowel disease, including risks of infection and malignancy.
Guest host Sara Horst, MD, talks with Dr Jordan Axelrad about two studies on safety of advanced therapies for inflammatory bowel disease, including risks of infection and malignancy.
Guest host Sara Horst, MD, talks...
06/06/2025
Advances in Inflammatory Bowel Disease Network
IBD Drive time logo
Podcast
IBD Drive Time: Miguel Regueiro, MD, on Providing Multidisciplinary Care in IBD
05/21/2025
Miguel D. Regueiro, MD; Raymond Cross, MD
Dr Regueiro and IBD Drive Time host Raymond Cross, MD, discuss the importance and the challenges of providing multidisciplinary care to patients with IBD, including dietary guidance, mental health services, and more.
Dr Regueiro and IBD Drive Time host Raymond Cross, MD, discuss the importance and the challenges of providing multidisciplinary care to patients with IBD, including dietary guidance, mental health services, and more.
Dr Regueiro and IBD Drive Time...
05/21/2025
Advances in Inflammatory Bowel Disease Network
IBD Drive time logo
Podcast
Edward Barnes, MD, on Antibiotics and Risk of Pouchitis
05/20/2025
Edward L. Barnes; Sara Horst, MD
Guest host Sara Horst, MD, talks with Dr Ed Barnes about his research into whether antibiotics taken a year before an IPAA may contribute to the development of pouchitis.
Guest host Sara Horst, MD, talks with Dr Ed Barnes about his research into whether antibiotics taken a year before an IPAA may contribute to the development of pouchitis.
Guest host Sara Horst, MD, talks...
05/20/2025
Advances in Inflammatory Bowel Disease Network
IBD Drive time logo
Podcast
IBD Drive Time: Edward Barnes, MD, on Pouch Complications
05/09/2025
Guest host Sara Horst, MD, and Dr Edward Barnes discuss complications of ileal pouch-anal anastamosis surgery and whether recent use of antibiotics puts patients at risk of pouchitis.
Guest host Sara Horst, MD, and Dr Edward Barnes discuss complications of ileal pouch-anal anastamosis surgery and whether recent use of antibiotics puts patients at risk of pouchitis.
Guest host Sara Horst, MD, and...
05/09/2025
Advances in Inflammatory Bowel Disease Network
IBD Drive time logo
Podcast
IBD Drive Time: Sara Horst, MD, on the Best of ECCO
04/22/2025
Raymond Cross, MD; Sara Horst, MD
Host Raymond Cross, MD, talks with Dr Sara Horst from Vanderbilt University about their picks for the most interesting and important presentations on inflammatory bowel disease at ECCO 2025.
Host Raymond Cross, MD, talks with Dr Sara Horst from Vanderbilt University about their picks for the most interesting and important presentations on inflammatory bowel disease at ECCO 2025.
Host Raymond Cross, MD, talks...
04/22/2025
Advances in Inflammatory Bowel Disease Network

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use